Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07536061 | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease | PHASE1 | RECRUITING | 32 | — | — | May 12, 2026 | Nov 30, 2027 | Jun 4, 2026 | 2 | New Zealand |
| Arm | Type | Description |
|---|---|---|
| Cohort 1: SRP-1005 Dose 1 | EXPERIMENTAL | Participants will receive SRP-1005 or placebo. |
| Cohort 2: SRP-1005 Dose 2 | EXPERIMENTAL | Participants will receive SRP-1005 or placebo. |
| Cohort 3: SRP-1005 Dose 3 | EXPERIMENTAL | Participants will receive SRP-1005 or placebo. |
| Cohort 4: SRP-1005 Dose 4 | EXPERIMENTAL | Participants will receive SRP-1005 or placebo. |
| Name | Type | Description |
|---|---|---|
| SRP-1005 | DRUG | Subcutaneous injection |
| Placebo | DRUG | Subcutaneous injection |
Key Inclusion Criteria: * Genetically confirmed diagnosis of huntingtin (HTT) cytosine-adenine-guanine repeat length ≥40. * Participant has HD Integrated Staging System (HD-ISS) Stage 2 or Mild Stage 3. At screening, the participant must be classified with the Enroll-HD HD-ISS Modified Calculator a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Votoplam |
| Neurocrine Biosciences, Inc. | NBIX | 2 | PHASE3 | Valbenazine |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE1 | ALN-HTT02 |
| uniQure N.V. | QURE | 2 | PHASE1 | intra-striatal rAAV5-miHTT |
| Sarepta Therapeutics, Inc. | SRPT | 1 | PHASE1 | SRP-1005 |